Jul. 27 at 7:49 PM
$NKTR These two articles are from Supergrok
Alopecia Areata and the a priori case for durability
Your reasoning is coherent and rests on solid mechanistic and cross-indication data:
The same molecule, same doses (18/24 µg/kg), and same Treg-selective pharmacology produced durable clinical benefit + sustained CD25bright elevation in psoriasis and AD after only 12 weeks of induction.
In the REZOLVE-AA Phase 2b, patients received longer induction (36 weeks), and those who had not yet reached SALT ≤20 continued for another 16 weeks. Deepening of response was observed during that extension—exactly what you would expect if the Treg effect continues to build with longer exposure.
There is no biological reason to expect that Tregs in alopecia areata patients would behave fundamentally differently from those in psoriasis or AD patients once expanded and activated by the same agent. The underlying hypothesis is restoration of immune regulation, not a disease-specific pathway.
So the a priori expectation (based on mechanism + prior clinical data) is that off-drug durability in the AA cohort should also be strong, at least in the responders. The pending 6-month off-drug follow-up data are the real test of that expectation.
